Skip to main content
. Author manuscript; available in PMC: 2021 Nov 8.
Published in final edited form as: J Subst Abuse Treat. 2018 Jul 31;94:81–90. doi: 10.1016/j.jsat.2018.07.014

Table 3.

Cost-effectiveness results for re-engineered methadone (2015 $).

Treatment Arm N Average total cost
of treatment per
participant
episode		 Past 30 days abstinent from heroin in
30 days prior to 12-month follow-up (self-
reported)		 Percentage of participants with a negative
opioid urine screen at 12-month follow-up		 Percentage of participants not meeting
DSM-IV criteria for opioid dependence at
12-month follow-up
Average cost
(SE)		 Mean
effectiveness ±
(SE)		 Incremental CE
ratio
(ΔC/ΔE)		 Mean
effectiveness ±
(SE)		 Incremental CE
ratio
(ΔC/ΔE)		 Mean
effectiveness ±
(SE)		 Imputed
incremental CE
ratio
(ΔC/ΔE)
TAU 149 $2292 20.2 40% – 31%
(108.26) (1.01) (4.02) – (3.80)
PCM 146 $2396 20.6 $242 39% Economically dominated 40% $1138
(102.64) (1.00) (4.05) – (4.06)

Note: Standard errors (SE) are presented in parenthesis.